希罗达联合奥沙利铂治疗晚期胃癌的临床疗效观察

目的：观察希罗达（Xeloda）联合奥沙利铂（L—OHP）治疗晚期胃癌的疗效和毒副作用。方法：L—OHP130mg／m2，加入5％GS500rrd中静脉滴注2小时，第一天，Xeloda1000mg／m2，2次／d口服，第1—14天，21天为一周期，连用2个周期后评价疗效。结果：23例患者中，CR1例PR11例SD8例PD3例，RR52．2％，中位疾病进展时间（TTP））5．8个月（3—8个月），中位生存期（MST）11个月（6—17个月），1年生存率34．8％。毒副反应主要为骨髓抑制、消化道反应、神经毒性和手足综合征，大多能耐受。结论：希罗达联合奥沙利铂治疗晚期胃癌具有较好的疗效，毒副作用小，能显著提高患者的生活质量，值得临床推广。

Clinical study of Xeloda (capecitabine) plus oxaliplatin (L-OHP) in treatment of advanced gastric carcinoma

Objective:To evaluate the efficacy and toxicity of Xeloda(capecitabine) plus Oxaliplation(L-OHP) in the treatment of advanced gastric carcinoma.Methods:L-OHP was administered at a dose of 130mg/m2 with 500ml of 5%GS by drip infusion for 2 hours on day 1,Xeloda 1000mg/m2 twice daily was adopted orally on day 1-14.The chemotherapy was repeated every 21 days and the efficacy was evaluated after 2 cycles.Results:Twenty-one patients were evaluable for treament outcome.One obtained CR,11 PR,8 SD,3 PD,and the overall response rate was 52.2%,TTP was 5.8 months(3-8months),MST was 11 months(6-17months) and one-year survival rate was 34.8%.The major toxicity and side effets were myelosuppression and gastrointestinal,neural toxicity and hand-foot syndrome,but they were acceptable.Conclusion:Xeloda plus L-OHP is a effective regimen for patient with advanced gastric carcinoma,less side effects.